Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MicroPort CardioFlow Medtech Corp. ( (HK:2160) ) has provided an announcement.
MicroPort CardioFlow Medtech Corporation has scheduled a board meeting for March 30, 2026, to review and approve the audited annual results for the year ended December 31, 2025. The board will also consider the publication of these results and evaluate whether to recommend a final dividend for shareholders.
The announcement signals the upcoming disclosure of the company’s financial performance, which will be closely watched by investors for indications of operational progress and profitability. Any decision on a final dividend could affect shareholder returns and may reflect management’s confidence in cash flow, balance sheet strength, and future business prospects.
The most recent analyst rating on (HK:2160) stock is a Sell with a HK$0.74 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.
More about MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corporation is a Hong Kong-listed medical technology company incorporated in the Cayman Islands. The group operates in the cardiovascular medtech sector through its subsidiaries, focusing on the development and commercialization of interventional products and solutions for heart-related conditions in Mainland China and international markets.
Average Trading Volume: 1,983,799
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.46B
Learn more about 2160 stock on TipRanks’ Stock Analysis page.